GSK's Jemperli meets overall survival primary endpoint in PhIII study
GSK announced that its checkpoint inhibitor Jemperli added to chemotherapy helped endometrial cancer patients live longer than chemotherapy in a Phase III study.
In the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.